title: Effects of encainide and its metabolites on energy requirements for defibrillation.
abstract: Encainide, a class IC antiarrhythmic agent, has been associated with proarrhythmic responses of ventricular tachycardia and fibrillation requiring defibrillation in patients. We examined the short-term effects of intravenous encainide and its two major metabolites, O-demethyl-encainide (ODE) and 3-methoxy-ODE (MODE), on the energy requirements for successful defibrillation in 25 pentobarbital-anesthetized, open-chest dogs. Truncated exponential (60% tilt) defibrillation shocks were administered through right atrial spring and left ventricular epicardial patch electrodes identical to those used in man with the automatic implantable defibrillator. At baseline multiple shocks of varying energy were applied to construct curves of percent successful defibrillation as a function of energy (DF curves) for each animal. Encainide, ODE, or MODE was then infused in loading and maintenance doses to achieve QRS widening of 20% to 50%. Saline was administered to animals serving as controls. Determination of the DF curve was repeated, after which the infusion was discontinued. After 1 hr washout period, an additional DF curve was constructed. The data were analyzed by logistic regression, and the energies required for 50% successful defibrillation (E50) were compared. No significant differences existed between the four groups in body or heart weight, extent of QRS widening, or baseline E50 values. After administration of encainide and ODE, the E50 increased by 129 +/- 43% (p less than .001) and 76 +/- 34% (p less than .005), respectively. Return of E50 toward baseline was observed after the washout periods in both groups (p less than .025), demonstrating the reversibility of the drugs' effects.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: E S
authors.initials: ES
authors.lastname: Fain
authors.forename: P
authors.initials: P
authors.lastname: Dorian
authors.forename: J M
authors.initials: JM
authors.lastname: Davy
authors.forename: R E
authors.initials: RE
authors.lastname: Kates
authors.forename: R A
authors.initials: RA
authors.lastname: Winkle
mesh_terms: D000813:Anilides / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D004285:Dogs; D004554:Electric Countershock / Q000379:methods; D004562:Electrocardiography; D004567:Electrodes, Implanted; D016700:Encainide / Q000031:analogs & derivatives; D005260:Female; D008297:Male; D013610:Tachycardia / Q000503:physiopathology; D013997:Time Factors
chemical_list: D000813:Anilides; D000889:Anti-Arrhythmia Agents; C033635:O-demethylencainide; C033636:3-methoxy-O-demethylencainide; D016700:Encainide